title: A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
abstract: CSL112 is apoA-I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high-density lipoprotein (HDL)-particles suitable for infusion. CSL112 is in development for the potential treatment of acute coronary syndromes (ACS) by optimizing cholesterol efflux. This study assesses the pharmacokinetics (PK), safety and tolerability of CSL112. Repeat doses of CSL112 or placebo were administered intravenously once- (3.4 g or 6.8 g) or twice-weekly (3.4 g) to healthy subjects in a placebo-controlled, randomized (3 CSL112: 1 placebo), ascending-dose study (NCT01281774). Twenty-seven subjects received CSL112 and nine received placebo. Study endpoints included plasma apoA-I and PC concentrations and specific PK parameters. CSL112 infusions immediately produced robust increases in apoA-I concentration in a dose-proportional manner, reaching levels higher than observed with currently available or investigational HDL products. After infusion of CSL112, apoA-I levels remained above baseline for approximately 3 days. Multiple infusions of CSL112 were safe and well tolerated with no evidence of major organ toxicity or immunogenicity. CSL112 may provide a novel option to rapidly transport cholesterol from atherosclerotic plaque to the liver and reduce early recurrent events following ACS. The data presented here support continued clinical development of CSL112 in patient populations.
authors.affiliation: CSL Behring, King of Prussia, PA, USA.
authors.forename: Rachael
authors.initials: R
authors.lastname: Easton
authors.forename: Andreas
authors.initials: A
authors.lastname: Gille
authors.forename: Denise
authors.initials: D
authors.lastname: D'Andrea
authors.forename: Roslyn
authors.initials: R
authors.lastname: Davis
authors.forename: Samuel D
authors.initials: SD
authors.lastname: Wright
authors.forename: Charles
authors.initials: C
authors.lastname: Shear
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D016632:Apolipoprotein A-I / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008075:Lipoproteins, HDL / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D010713:Phosphatidylcholines / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D055815:Young Adult
chemical_list: D016632:Apolipoprotein A-I; C584257:CSL112; D008075:Lipoproteins, HDL; D010713:Phosphatidylcholines; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin
keywords: CSL112; acute coronary syndrome; apolipoprotein A-I; pharmacokinetics; reconstituted HDL